• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of May 13


The Center for Biosimilars® recaps the top news for the week of May 13, 2019.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 13.

Number 5: The Generic Biosimilar Medicines Association has launched an educational hub for biosimilars.

Number 4: Biosimilar developer Biocon said this week that it will share in the global profits of Hulio, an adalimumab biosimilar.

Number 3: Set against a backdrop of rising concern about the cost of insulin, the FDA held a hearing about biosimilar insulins.

Number 2: Last week, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.

Number 1: AbbVie announced that it has settled its patent litigation with Boehringer Ingelheim over adalimumab.

Finally, last week, our e-newsletter asked how comfortable you think patients and providers should be about switching among biosimilars of the same product.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Related Content
© 2024 MJH Life Sciences

All rights reserved.